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Using a sensitive transfection-tumorigenicity assay, we have isolated a novel transforming gene from the
DNA of two patients with chronic myelogenous leukemia. Sequence analysis indicates that the product of this
gene, axl, is a receptor tyrosine kinase. Overexpression of axl cDNA in NIH 3T3 cells induces neoplastic
transformation with the concomitant appearance of a 140-kDa axl tyrosine-phosphorylated protein. Expression
of axl cDNA in the baculovirus system results in the expression of the appropriate recombinant protein that is
recognized by antiphosphotyrosine antibodies, confirming that the axl protein is a tyrosine kinase. The
juxtaposition of fibronectin type III and immunoglobulinlike repeats in the extracellular domain, as well as
distinct amino acid sequences in the kinase domain, indicate that the axl protein represents a novel subclass of
receptor tyrosine kinases.
Receptor tyrosine kinases represent a class of proteins
that transduce signals from the extracellular milieu into the
cytoplasm by binding peptide growth factors. These growth
factors and their cognate receptors are involved in regulating
cellular growth and differentiation. Alteration of either
growth factors or their receptors can result in neoplastic
transformation and altered development (12). There are
several mechanisms by which growth factor receptors can be
rendered transforming. Retroviral transduction of proto-
oncogenes can result in truncation and mutation of the
normal version of the gene. This has been shown for the
epidermal growth factor receptor (EGFR) (v-erbB) (18),
colony-stimulating factor 1 receptor (CSF-1R) (v-fms) (68),
and ros (v-ros) (52) genes. Overexpression of an otherwise
normal receptor, with or without the concomitant applica-
tion of ligand, can also result in neoplastic transformation, as
shown for the insulinlike growth factor 1 receptor (38),
EGFR (15, 77), CSF-1R (65), eph (51), and neu (16) genes.
Furthermore, structural rearrangement, as seen with ret, trk,
and met (24, 50, 59), may also activate the transforming
capacity of receptor kinases.
In addition to the transforming activity of altered or
overexpressed receptor tyrosine kinases, studies have dem-
onstrated that the normal cellular homologs of these recep-
tors function to regulate cell growth and differentiation.
Examples include the trk receptor kinase originally isolated
by genomic transfection of human colon carcinoma DNA
into NIH 3T3 cells (50). Although trk is not generally
involved in colon cancer, recent work has demonstrated that
this gene encodes a subunit of the nerve growth factor
receptor which plays a critical role in neural development
(39, 40). Furthermore, the met proto-oncogene, originally
isolated by transfection of 3T3 cells with genomic DNA from
the tumorigenic human osteogenic sarcoma cell line MNNG-
* Corresponding author.
t Present address: Department of Internal Medicine, Hematol-
ogy, Universitaets Klinikum Rudolf Virchow, Spandauer Damm
130, D-W1000 Berlin, Germany.
HOS (10), has been demonstrated to be the cell surface
receptor for hepatocyte growth factor, a potential growth
factor for a broad spectrum of cell types as well as a
mediator of liver regeneration (7). In addition, CSF-1R
mediates the pleiotropic effects of its cognate ligand, CSF-1.
Together, these two molecules stimulate the proliferation
and differentiation of cells of the macrophage lineage (68).
In an effort to determine genes involved in the progression
of chronic myelogenous leukemia (CML) to acute-phase
leukemia, we previously reported the identification of a
transforming gene in the DNAs of two patients with CML
(47). Molecular cloning and characterization indicate that
this gene, which we term axl (from the Greek word anex-
elekto, or uncontrolled), is a receptor tyrosine kinase with a
structure novel among tyrosine kinases. Our data indicate
that the ax! protein has tyrosine kinase activity and is
capable of transforming NIH 3T3 cells. Furthermore, axl's
transforming capacity results from overexpression of axl
mRNA rather than from structural mutation.
MATERIALS AND METHODS
Identification of a transforming gene in CML cells. Trans-
fections and nude mouse tumorigenicity assays were per-
formed as described previously (47). The cell lines AF6295
and AF3642 were derived from secondary nude mouse
tumors arising from transfection of DNA from blast crisis
and chronic-phase CML patients, respectively. Tumors
were isolated from nude mice and digested in the presence of
trypsin-EDTA. A portion of these cells was then plated in
plastic tissue culture flasks.
Isolation of cosmid and cDNA clones. DNA fragments for
cosmid cloning were generated by partial MboI digests of
genomic DNA from a secondary nude mouse tumor cell line,
AF6295. The restricted DNA fragments were size selected
on sodium chloride gradients and cloned in the c2RB cosmid
vector as previously described (4). Following ligation, re-
combinants were packaged with Gigapack Gold (Stratagene,
La Jolla, Calif.) according to the manufacturer's recommen-
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dations and used to infect Escherichia coli W46-4. The
cosmid library was screened by using the Blur8 probe, which
contains human Alu repetitive sequences (37), resulting in
the identification of two Alu-positive clones, 1-1 and 4-2.
Unique human exon fragments were identified by differ-
ential screening of Southern blots of cosmid clones 1-1 and
4-2. Poly(A)+ RNA from both AF6295 and untransformed
NIH 3T3 cells was obtained as previously described (1).
First-strand cDNA reactions were performed in a 50-,ul final
volume of 0.6 mM dCTP, 1 mM each dATT, dGTT, and
dTTP, 10 mM dithiothreitol, 20 U of RNasin, 100 ,ug of
random hexamers (Pharmacia, Piscataway, N.J.) per ml, 100
,uCi of [32P]dCTP (3,000 Ci/mmol; Dupont/NEN), lx re-
verse transcriptase buffer (50 mM Tris [pH 8.3], 50 mM KCl,
10 mM MgCl2, 1 mM dithiothreitol, 1 mM EDTA, 100 mg of
bovine serum albumin [BSA] per ml, 20 U of avian myelo-
blastosis virus reverse transcriptase (Promega, Madison,
Wis.), and 200 ng of poly(A)+ mRNA. The mixture was
incubated at 42°C for 45 min and denatured at 95°C for 5 min.
Unincorporated label was separated on a Sepharose G-50
column. The resulting probes were used for Southern hy-
bridization (1), using sheared and denatured mouse or hu-
man DNA at 100 ,ug/ml and salmon sperm DNA at 100 p,g/ml
for blocking. Southern blots were also hybridized with Blur8
to identify fragments from the cosmid clones containing Alu
repeat sequences. A single 2.8-kb EcoRI-BamHI fragment
(pcc-1) in cosmid clone 1-1 was found to be free of Alu and
mouse sequences while containing transcribed exons from
the putative human transforming gene.
cDNA libraries were constructed in XgtlO by using
poly(A)+ RNA from AF6295. By using pcc-1 as a probe,
several cDNAs were identified. Sequence analysis of these
cDNAs indicated these clones were short (approximately 1
kb in size) and did not contain poly(A)+ tails. A full-length
cDNA, clone 1-4, was then isolated from a size-selected,
oligo(dT)-primed cDNA library constructed as described
previously (26) except that 4 ,ug of poly(A)+ RNA was
reversely transcribed by using Superscript Moloney murine
leukemia virus (Bethesda Research Laboratories, Gaithers-
burg, Md.). After second-strand synthesis, cDNA products
were fractionated on a 0.8% agarose gel in 1 x TAE (0.04 M
Tris-acetate, 0.002 M EDTA). Products in the range of 2.7 to
6 kb were electrophoresed onto NA-45 paper (Schleicher &
Schuell, Keene, N.H.) and then eluted twice with 250 ,lA of
elution buffer (1 M NaCl, 50 mM arginine, free base). The
eluate was extracted three times with phenol-chloroform
(1:1) and ethanol precipitated. cDNA products were ligated
in EcoRI-cut XgtlO arms (Stratagene), packaged into phage
heads with Gigapack Gold (Stratagene), and then plated on
E. coli C600Hfl. Recombinants were screened with an axl-
specific cDNA. Positive clones were subcloned into pBlue-
scriptIl-KS (Stratagene) for subsequent sequence analysis.
Normal axl cDNA clones were isolated as described
above, using a size-selected cDNA library constructed from
poly(A)+ RNA from the normal human diploid fibroblast cell
line IMR-90. Recombinant phage were screened by using a
polymerase chain reaction (PCR) probe generated from
clone 1-4 DNA, using primers PJA-14 (bp 2090 to 2109;
GCCCACTCAGATGCTAGTGA) and PJA-17 (bp 2569 to
2588; CAAGGCCTTCAGTGTGT7CT). Positive clones were
subcloned into pBluescriptll-KS for subsequent sequence
analysis.
DNA sequencing. Complete sequence from both strands
was determined by the dideoxy termination method (66),
using the modified T7 polymerase (Sequenase; United States
Biochemical, Cleveland, Ohio). Overlapping fragments for
sequence analysis were generated by digestion with exonu-
clease III (31) or by priming with sequence-specific oligonu-
cleotides. Sequences were compared with the BESTFIT
DNA sequence analysis program (University of Wisconsin
Genetics Computer Group [14]).
RNA-PCR analysis of axl expression. RNA (100 ng of
mRNA or 1 j.ig of total RNA) was denatured at 95°C for 3 to
5 min in the presence of 100 pmol of random hexamers
(Pharmacia) and cooled on ice for 2 min. The RNA was
reverse transcribed in a 20-,ul final volume of 1 x PCR buffer
(10 mM Tris [pH 8.3], 50 mM KCI, 1.5 mM MgCl2, 0.001%
gelatin), 625 jiM each deoxynucleoside triphosphate
(dNTP), 20 U of RNasin (Promega), 10 mM dithiothreitol,
and 200 U of Superscript Moloney murine leukemia virus
reverse transcriptase. The reaction mixture was incubated
for 10 min at room temperature, 45 min at 42°C, and 5 min at
95°C. One microliter of cDNA product was PCR amplified in
a 50-plA final volume of 10 mM Tris (pH 8.3), 50 mM KCl, 1.5
mM MgCl2, 200 ,uM each dNTP, 0.001% gelatin, 0.5 puM
each primer, and 1.25 U of Taq polymerase (Promega) for 30
cycles under the following conditions: 5 min at 94°C, 1 min at
55°C, 1.5 min at 72°C for 1 cycle; 1 min at 94°C, 1 min at
55°C, 1.5 min at 72°C for 28 cycles; 1 min at 94°C, 10 min at
60°C. Differential PCR (57) was performed, using a-actin as
a reference. Ten percent of this reaction mixture was elec-
trophoresed on a 12% polyacrylamide gel and stained with
ethidium bromide. Primer sequences are as follows: PJA-2
(bp 1847 to 1866), GGTGGCTGTGAAGACGATGA; PJA-3
(bp 2149 to 2130), CTCAGATACTCCATGCCACT; PJA-8
(bp 1320 to 1339), GAGGTGACCCTGGAGCTGCA; JB-2
(bp 1490 to 1471), AGGAGTTGAAGGTCCCTTCA; 5' a-ac-
tin, CCTTCCTGGGCATGG AGTCCT; and 3' t-actin, GGA
GCAATGATCTTGATCTTC.
Chromosomal localization and fluorescence in situ chromo-
somal hybridization. A Southern blot of DNA from human-
hamster somatic cell hybrids (BIOS, New Haven, Conn.)
was probed with random-primer-labelled cDNA clones 12-1
and 1-4 and genomic clone pcc-1 under conditions recom-
mended by the manufacturer. The filter was washed twice in
2x SSC (lx SSC is 0.15 M NaCl plus 0.015 M sodium
citrate)-0.5% sodium dodecyl sulfate (SDS) for 10 min at
room temperature, once in 1 x SSC-1.0% SDS for 15 min at
65°C, and twice in 0.1x SSC-L.O%o SDS for 15 min at 65°C
and then exposed overnight at -70°C.
For in situ hybridization, human metaphase cells were
prepared from phytohemagglutinin-stimulated peripheral
blood lymphocytes. The axl probe was cosmid 1-1 contain-
ing a 41-kb genomic fragment cloned in the cosmid vector
c2RB. The procedure used for fluorescence in situ hybrid-
ization is a modification of the method described by Lichter
et al. (45). Biotin-labelled probes were prepared by nick
translation using Bio-11-dUTP (Enzo Diagnostics, New
York, N.Y.). Chromosomal DNA was denatured by immer-
sion of the slides in 70% formamide-4x SSC (pH 7.0) at 70°C
for 2 min. Prior to hybridization, unlabelled, sonicated, total
human genomic DNA (150 mg/ml) was added to the hybrid-
ization mixture (50% formamide, 1x SSC, 10% dextran
sulfate, pH 7.0) containing the labelled probe (50 to 100 ng).
The hybridization mixture was heated at 75°C for 5 min and
then incubated at 37°C for 5 to 10 min to promote partial
reannealing. After hybridization, the slides were washed in
50% formamide-4x SSC (three washes, 5 min each) at 40°C
and then in 4x SSC at 40°C (three washes, 3 min each).
Detection reagents were prepared in 4x SSC-0.1% Triton
X-100-1% BSA, and the washes were performed in 4x
SSC-0.1% Triton X-100 at 40°C (three washes, 3 min each).
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For the detection of the labelled probe, slides were incu-
bated with fluorescein isothiocyanate-conjugated avidin (5
mg/ml; Vector Laboratories, Burlingame, Calif.) at 37°C for
30 min and then washed. Metaphase cells were counter-
stained with 4,6-diamidino-2-phenylindole dihydrochloride
(200 ng/ml in 2x SSC, 5 min, room temperature; Sigma, St.
Louis, Mo.) and mounted in 20 mM Tris-HCl (pH 8.0)-90%
glycerol containing 2.3% DABCO antifade (Sigma). The
slides were examined under a Zeiss microscope equipped
with epifluorescence optics.
Hybridization analysis. Northern (RNA) and Southern
analyses were performed according to standard protocols
(1). RNAs were isolated from cell lines by the method of
Glisin et al. (23) or Chomczynski and Sacchi (9). Radiola-
belled probes were generated by the random-priming tech-
nique or PCR (21, 35), using the primer pairs PJA-2 and
PJA-3 (see above); PJA-8 (see above) and PJA-9 (bp 1890 to
1871; CTGACCTCGTGCAGATGGCA); PJA-11 (bp 646 to
627; TGAGCTTGGCAGCTCAGGTT) and PJA-12 (bp 248
to 267; GCAGGCTGAAGAAAGTCCCT); and PJA-14 (bp
2090 to 2109; GCCCACTCAGATGCTAGTGA) and PJA-17
(bp 2569 to 2588; CAAGGCCTTCAGTGTGTTCT).
Transfection and tumorigenicity assays. A 100-mm dish
containing approximately 5 x 105 NIH 3T3 cells was fed
with fresh medium 4 to 24 h prior to transfection. Five
micrograms of plasmid DNA was precipitated with 3 M
sodium acetate in the presence of 30 pug of high-molecular-
weight salmon sperm DNA in a 100-,u volume. The resulting
precipitate was resuspended in 450 RI of H20 and incu-
bated overnight at 37°C with gentle rocking. On the following
day, 50 RI of 2.5 M CaCl2 was added dropwise while air was
bubbled through a plugged pipette. This solution was then
added dropwise to 500 pu1 of 2x HBS (280 mM NaCl, 50
mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid
[HEPES], 1.5 mM Na2HPO4- 12H20, pH 7.05) while air
was bubbled through a plugged pipette. This solution was
allowed to stand for 20 to 30 min at room temperature
without agitation. The fine precipitate was then exposed to
3T3 cells for 8 h at 37°C. The medium was removed, and 2 ml
of 15% (vol/vol) glycerol in phosphate-buffered saline (PBS)
was added to cells for 90 s. Cells were washed with PBS and
fed with fresh medium. After 24 to 48 h, cells were split 1:4
into 100-mm dishes containing G418 (600 ,ug/ml; total drug).
Emergent colonies were then pooled to produce the non-
clonal cell lines used in subsequent analysis (TF14A and
TF14B transfected with the axl+ sense construct; TF15A
and TF15B transfected with the axl+ antisense construct;
TF16A and TF16B transfected with the pLXSN vector).
For analysis of transformation, half of the pooled G418-
resistant cells were passaged once, grown to confluence, and
scored for focus formation after 2 to 3 weeks. The remainder
of these cells were expanded and injected into the flanks of
athymic nude mice at concentrations of 1 x 105 and 5 x 105
cells per site. Tumor formation was scored 50 days after
injection.
Baculovirus expression. The baculovirus transfer vector
pBlueBac (Invitrogen, San Diego, Calif.) contains a ,-galac-
tosidase expression cassette which permits recombinant
plaque screening by addition of the chromagenic substrate
X-Gal (5-bromo-4-chloro-3-indolyl-13-D-galactoside; 0.15 mg/
ml) to the agarose overlay. The cDNA insertion site of
pBlueBac is an NheI site. An axl cDNA segment with
full-length coding sequence and NheI-compatible ends was
produced by cutting the axl cDNA clone 1-4 at the transla-
tion start site with NcoI. The resulting 3' overhangs were
filled in with the Klenow fragment ofDNA polymerase I plus
dNTPs. After heat inactivation, the fragment was digested
with EcoRI, ligated into Smal-EcoRI-digested pBluescriptll-
KS plasmid, and then used to transform E. coli. The result-
ing plasmid contains an Spel site 12 bp upstream of the axl
ATG start site and an XbaI site 265 bp downstream of the
translation stop site. This SpeI-XbaI fragment was cloned
into NheI-digested pBlueBac. The resulting axl transfer
vector and wild-type Autographa californica nuclear poly-
hedrosis virus DNA were cotransfected into Spodoptera
frugiperda Sf9 cells (72). Subsequent plaque selection
yielded the recombinant virus axl-BIBac. Positives were
evaluated for the presence of axl sequences with PCR, using
primer pair PJA-5 (bp 951 to 970; TCAGACGATGGGATG
GGCAT) and PJA-6 (bp 1006 to 1025; CACGGATG CTTGC
GAGGTGA) or PJA19 (bp 2755 to 2774; ATGTCCTCTGC
CCTTCCACA) and PJ-7 (bp 2827 to 2843; TCAGGCACCA
TCCTCCT).
Immunoblot analysis of axl expression. For analysis of
baculovirus expression, Sf9 cells were grown at 27°C in
monolayers (2 x 106 cells per 60-mm dish) in TMN-FH
medium (Invitrogen) and infected with wild-type or axl-
BIBac virus at a multiplicity of infection of greater than 10.
After 1, 2, and 3 days, the dishes were placed on ice and the
cell monolayers were rapidly rinsed with PBS, lysed, and
then scraped in 0.3 ml of RIPA buffer (50 mM Tris-HCl [pH
7.4], 150 mM NaCl, 5 mM EDTA, 1% Triton-X 100, 1%
sodium deoxycholate, 0.1% SDS, 100 puM Na3VO4, 0.5 mM
phenylmethylsulfonyl fluoride, 2.5 mM p-nitrophenylphos-
phate). After addition of 0.15 ml of 3 x Laemmli gel sample
loading buffer (30 mM Tris-HCI [pH 7.8], 9% SDS, 15%
glycerol, 6% 2-mercaptoethanol, 0.05% bromophenol blue)
and boiling for 5 min at 100°C, 50-,il aliquots of the samples
were electrophoresed on 9% SDS-polyacrylamide gels. The
proteins were electrotransferred from the gel onto a polyvi-
nyl difluoride membrane (Immobilon-P; Millipore, Bedford,
Mass.). The membrane was treated for 30 min with 150 mM
NaCl-10 mM Tris-HCl (pH 7.5)-0.05% Tween-20 (TBST)
containing 1% BSA. The blot was then incubated for 1 h with
antiphosphotyrosine monoclonal antibody PT-66 (Sigma)
diluted 1:2,000 in TBST. Using a duplicate blot, 1 mM
phenylphosphate was included with the antiphosphotyrosine
antibody to block specific binding to phosphotyrosine. The
blot was rinsed three times for 5 min each time with TBST
and then incubated with anti-mouse immunoglobulin G-alka-
line phosphatase conjugate (A-5153; Sigma) diluted 1:2,000
in TBST for 45 min. After three rinses in TBST, the blot was
incubated with the chromagenic substrates nitroblue tetra-
zolium (0.33 mg/ml) and 5-bromo-4-chloro-3-indolylphos-
phate (0.165 mg/ml) in alkaline buffer (100 mM Tris [pH 9.5],
100 mM NaCl, 10 mM MgCl2) for 5 to 20 min. Color
development was stopped by rinsing with deionized water.
Analysis of tyrosine-phosphorylated proteins in the axl-
transformed 3T3 cells (see Fig. 7B) was performed according
to published protocols (53).
The polyclonal anti-axl antiserum was prepared by immu-
nizing rabbits with gel-purified baculovirus-expressed axl
protein. The antigen in the form of a Coomassie-stained gel
slice was processed and administered in primary and (after 1
month) boost injections (28). The anti-axl serum was col-
lected 25 days following the boost injection. Immunoblot
analysis was performed with the anti-axl antiserum and
preimmune serum diluted 1:3,000 in TBST. Anti-rabbit im-
munoglobulin G-alkaline phosphatase conjugate was used as
the secondary antibody.
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FIG. 1. Expression of axl in nude mouse tumors. Poly(A)+ RNA
from various nude mouse tumors was fractionated on a formalde-
hyde-agarose gel, transferred to nylon, and probed with pcc-1
labelled by random priming (21). Lanes: A, untransformed NIH 3T3
cell line; B, EJ-ras-transformed NIH 3T3 cell line 1; C, EJ-ras-
transformed NIH 3T3 cell line 2; D, AF6295-1; E, AF6295-2; F,
AF3642. Samples in lanes D and E are from two different passages
of the nude mouse tumor explant cell line derived from transfections
with DNA from a CML blast crisis patient. AF3642 is another
explant cell line derived from transfection with DNA from a CML
chronic-phase patient. The single band seen in lanes A through C
represents the normal mouse homolog of axl. Arrowheads indicate
the positions of 28S and 18S rRNAs.
RESULTS
Cloning of the transforming axl gene. In our previous
study, using a sensitive NIH 3T3 transfection-tumorigenicity
assay, we identified a transforming gene in the DNA from
the peripheral leukocytes of two CML patients that lacked
ras mutations (47). The resulting tumors arising from sec-
ondary transfection of tumor DNA gave rise to two explant
tumor cell lines (AF6295 and AF3642) which harbored the
same unique transforming human sequences. Several cosmid
clones bearing human Alu repeats were isolated from a
cosmid library derived from the DNA of one such explant
tumor cell line, AF6295 (see Materials and Methods). Exon
mapping identified a genomic fragment, pcc-1, that con-
tained transcribed human sequences but was devoid of Alu
repeats and mouse exons. Using pcc-1 as a probe on
Northern blots, two axl mRNA species of 5.0 and 3.4 kb
were identified in the explant 3T3 cell lines from the CML
transfectants but not in untransformed NIH 3T3 cells or in
3T3 cells transformed by a mutant H-ras oncogene (Fig. 1).
Using pcc-1 as a probe, several axl-specific cDNA clones
were isolated from cDNA libraries derived from AF6295
poly(A)+ RNA. All hybridized to the same 5.0- and 3.4-kb
transcripts in the nude mouse tumor explant cell lines on
Northern blot analysis. Sequence analysis of these cDNAs
showed sequences in common with pcc-1. Since the original
cDNA clones were short and did not contain poly(A)+ tails,
a size-selected cDNA library was screened to identify full-
length cDNAs. Several clones were isolated and found to
contain 3.2-kb inserts consistent in size with one of the two
axl mRNA species. One of these clones, 1-4, was subcloned
and sequenced.
Sequence analysis indicates that axl is a novel receptor
tyrosine kinase. The sequence of clone 1-4 predicted a
protein of 894 amino acids with two in-frame methionine
residues that are candidate initiating amino acids based on
Kozak consensus rules (Fig. 2) (43). Furthermore, an in-
frame termination codon lies 170 bp upstream from the first
methionine codon. This methionine marks the beginning of a
potential signal sequence of 32 amino acids (78). A search of
the EMBL, GenBank, and NBRF protein data bases indi-
cated that the axl protein is a novel protein tyrosine kinase
with significant homology to many known kinases, in partic-
ular eph, eck, elk, ros, trk, insulin receptor, insulin-related
receptor, insulinlike growth factor 1 receptor, and sevenless
(4, 19, 32, 44, 46, 49, 52, 69, 75) (Fig. 3B and C). The
predicted peptide at amino acids 543 to 569 contained the
consensus sequence GxGxxG...(15 to 20 amino acids)
...AxKxM, which functions as the Mg2+-ATP binding site
for tyrosine kinases (27). At approximately 100 amino acids
carboxyl terminal to the Mg2+-ATP binding domain in axl
lies the sequence DLAARN...(34 amino acids)...PVKWI
AIE, which resembles but is distinct from a consensus
sequence specific to tyrosine kinases, DLAARN...P(I/V)(K/
R)W(T/M)APE (27). Furthermore, there are two sites at
amino acids 779 and 821 in the carboxyl terminus of axl that
are similar to the consensus sequence (E/D)(E/D)(E/D)(E/D)
(E/D)Y(M/V)PMXX, where Y is phosphotyrosine, for a
phosphatidylinositol (Ptdlns) 3-kinase binding site (8). These
observations suggest that axl is a tyrosine kinase that inter-
acts intracellularly with Ptdlns 3-kinase.
Amino acids 448 to 472 in the axl protein comprise a
hydrophobic region consistent with a transmembrane do-
main (Fig. 2 to 4). Within the putative extracellular domain,
sequences (amino acids 224 to 428) amino terminal to the
transmembrane region of the axl protein encode two fi-
bronectin type III (FNIII) repeats (62, 71). Amino terminal
to the FNIII repeats in axl (amino acids 37 to 212) are two
immunoglobulinlike (IgL) repeats (79). Highly conserved
cysteine and tryptophan residues (designated by asterisks in
Fig. 3A) are characteristic of IgL domains. In addition, the
extracellular domain of the axl protein contains six consen-
sus sites for N-linked glycosylation, NxT/S, predicting that
the mature axl protein is glycosylated. The juxtaposition of
IgL and FNIII repeats in the extracellular region of the axl
protein has not been reported for any known receptor
tyrosine kinase, thus making the axl protein unique among
this class of proteins.
Biologic activity of axl. Using cDNA clone 7-1 as a probe
for Southern hybridization with nude mouse tumor DNAs,
we detected human axl sequences in the appropriate primary
and secondary tumors, indicating that axl was the transform-
ing gene passaged with each cycle of transfection (data not
shown).
To confirm axl's transforming potential, we constructed
retroviral expression vectors containing the full-length axl
cDNA (clone 1-4). In these constructs, transcription of axl is
under the control of a Moloney murine sarcoma virus long
terminal repeat, whereas the neomycin phosphotransferase
gene, which confers resistance to the drug G418, is driven by
a simian virus 40 promoter (55). NIH 3T3 cells were trans-
fected with the axl sense (pL1-4S) or antisense (pLl-4AS)
construct or vector alone (pLXSN) and then assayed for
transformation in a standard focus formation assay (i.e.,
without G418 selection). No foci were observed in the focus
formation assay. Furthermore, colonies arising after G418
selection did not appear transformed. However, when the
G418-resistant colonies were passaged once and allowed to
reach confluence, foci emerged in the cells transfected with
pL1-4S (axl+ sense construct) but not pL1-4AS (axl+ an-
tisense construct) or pLXSN (vector) (Fig. 5). This finding
suggests that axl alone is necessary but insufficient for
transformation in this system and that either a second
genetic event or selection for cells overexpressing axl is
required for axi to be transforming. Northern analysis was
performed on RNA isolated from the initial pooled G418-
resistant cells (cells transfected with the sense axl, TF14A
and TF14B; cells transfected with the anti-sense axl, TF1SA
VOL . 1l, 1991
5020 O'BRYAN ET AL. MOL. CELL. BIOL.
axl+ 39 GTGGC
1 M A R C P R M G R V P L A C
axl+ 159 AGGGGC=CI G=


























































L A L C GHW A C N A P R G
I I W n;GCCCAGGC
-----------First Y-noglobulin-LikeI




TO0 A E S P F V G-- -A P C
L R D G Q I L E L A D
S T Q T Q V P L G E D E Q D D W I V V S Q L R I T S L Q L S D T G Q Y Q C L V F I
AGCACCCAG ATGC TG AGCTTTCCGACACG GIGCA !CGG7TGGT
L G H Q T F V S Q P G Y V G L E G L P Y F L e E P E D R T V a a N T P F N L S C
-----Second lnmoglobulin-Like Damin------------------------------------------------------------------- #-------
Q a Q G P P E P V D L L W L Q D A V P L A T A P G H G P O R S L H V P G L N K T
CTCAGr.DCDCAGAGCCCGTGGA C C_LR_L LT YGCATGTTCCAG LVFGAACAA
_- \ /-
S S F S C E A H N a K G V T T S R T A T I T V L P QQP R N L H L V S R Q P T E
LGH TFVS GY GLEGLPYFLK P RTVAANTCPAC FLGSCTCACACGGAG
-----SFcrsdFIbrouncin Tpn III in------------------------------------------------------------------------------
L E V a PT P L T H C T L a v L S D D GP G I A G E P D P P E
~~~~~~~~~AC T= _ x _ i_C_A__ ATGGA WTCGCCJGAGAAG
E P L T S Q A S V P P H Q L R L G S L H P H T P Y H I R V a C T S S Q G P S S N
GAOCTAC7CAOCAACTCCGTCCCCATCAGCTTKCAGAGCCCATCCTAnUCACCCUTT
----\l Fncnu/- -------------------------------------- #- ----- --SecondFibrn--ctinTyIII- -
T H W L P V E T P E G V P L G P P E NI S a T R N G S Q A F V H W Q E P R A P L
L
Q G T L L G Y R L a Y Q G Q D T P E V L tl D I G L R Q E V T L E L Q G D G S V S
CAL AWGGTLAGGGTGYGLLATCALAGCGCCCGCAATGGAC
N L T V C V A a Y T a A G D G P W S L P V P L E a w R P G A 0 P V H Q L V K E
AATCTGAC IG IIA;OCCT AC TSIII GTAcXGA Ca=A GOkAASCZ::lCAGC GCG
------------------------------dTranFnnnIbraneDIinD----------------------
P S T P A F S W P W W Y V L L G a v v A A A C V L I L A L F L V H R R K K E T R
Y G E V F E P T V E R G E L V V R Y R V R K S Y S R R T T E A T L N S L G I S E
THLPVET PEGVPLGPPKK ASlATRHGSOAFVHPRAPLATCAGTGAA
e L K E X L R D V M V D R H K V A L G K T L G E G E F G a v N E G Q L N Q D D S
~
I L X V a v x T N X I A I C T R S E L E D F L S E A V C 1 X E F D H P N V N R L
I G V C FL G S E R E S F P A P V V I L P F LK H G D L H S F L L Y S R L G D S
_W _ hN-iTcATCTTAt~~~~~~~~~~~~~~TCrTAGATClKTt =T%AATCGGACA
c
P V Y L P T GM L V X F M a D I a s G5 E Y L S T K R F I H R D L a a R N C KL
CCAGTGTAC;CTGC CCACTCAGATGCTAGlGAAATCTOAAACCAGTGGATGGCTTTGAGTACAGAGATTCATACACCGGACCGGGGCAGACTCTGCTG
N E N N S V C V a D F G L S X K I Y N G D Y Y R Q G R I a K N P V K W I A I E S
AAGA T;GlATGCAATOA;CAGGATCCTGL
L a D R V Y T S K S D V W S F G V T tl W E I a T R G Q T P Y P G V E N S E I Y D
CTtO7GCCGlGCA :ACCAOC A TGTGGGAGATTGCAAGGOCC AAACCCCAT
Y L R Q G N R L K Q P a D C L D G L Y a L tl S R C W E L N P Q D R P S F T E L R
PS T PA T SW P WG V L G CCA V V A A IIIT;GAC V TILA L F- LV H RR K K K T R
E D LK K T LE ALDYV ND E G G Y P E P P G a a G G a
I ~~~~~~~~~~~~~~~ATGTCAACATVTAGTGGT
.D P P T Q P D P K D S C S C L T A a E V H P a G R Y V L C P S T T P S P a Q P a
GACCCCACCCAGC CAGACCCTAAGGATTCC7GTAGtG=:TC _ AC>__X AACCCCTAGO ;CCAGCTGCT
.D R G S P A A P G Q E D G A 894
I GAT txALXA:_T ACTXAlC =TKlCTK;G TCCAACAAGCATAGCC Ac Z
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axl, A NOVEL, TRANSFORMING RECEPTOR TYROSINE KINASE 5021
FIG. 2. Sequences of axl cDNAs and predicted peptides. Shown are the complete nucleotide and amino acid sequences of clone 1-4 (axl+)
isolated from the nude mouse tumor cell line AF6295, with the predicted peptide sequence on the top line. Only the nucleotide differences
between clone 6-2 (axl-) and clone 1-4 are marked below the 1-4 nucleotide sequence. Differences in the predicted peptide sequence of clone
6-2 are indicated below the 6-2 nucleotide sequence with a boxed area highlighting these differences. The minus signs indicate sequences not
present in clone 6-2. Underlined area, signal peptide; #, potential N-linked glycosylation sites; *, conserved residues of the ATP-binding site
marking the beginning of the kinase domain; solid overlined area, putative autophosphorylation sites which potentially bind Ptdlns 3-kinase.
A stop codon (not shown) lies 170 bases upstream of the first methionine and was present in an overlapping cDNA clone which was 270 bp
more 5' of the beginning of 1-4.
and TF15B; cells transfected with the vector alone, TF16A
and TF16B) and transformed foci cloned from cells trans-
fected with the sense axl cDNA (subclones TF14B1, -14B2,
-14B3, -14B7, and -14B10). Expression of the human ax!
gene was seen in cells transfected by sense (TF14A and -B)
and antisense (TF15A and -B) constructs, albeit at low
levels. However, the axl-transformed subclones expressed
high levels of axl RNA (Fig. 6A). Thus, the second event in
axl transformation appears to be a selection for cells ex-
pressing increased levels of axl message, indicating that
overexpression of axl is necessary for 3T3 transformation.
We next tested the tumorigenic capacity of cells trans-
fected with the genomic axl gene (AF6295) or axl cDNA
(clones TF14B1, -14B2, -14B3, -14B7, and -14B10). Injection
of either AF6295 or clone TF14B1, TF14B2, TF14B3,
TF14B7, or TF14B10, all of which express high levels of axl
message, resulted in the emergence of tumors within 9 days
(Table 1). There appeared to be a rough correlation between
a short tumor latency with increased expression of axl RNA
and protein, further supporting the notion that axl overex-
pression drives 3T3 transformation. In contrast, the initial
axl transfectants (TF14A, TF14B, TF15A, and TF15B),
vector-transfected NIH 3T3 cells, and untransformed NIH
3T3 cells did not form tumors within an incubation period of
50 days except for one of the clones transfected with vector
alone (TF16A). This clone formed a tumor after 43 days and
therefore represents background tumor formation.
Tyrosine kinase activity of axl. To test whether axl is a
tyrosine kinase, we analyzed the phosphotyrosine profile of
cells transformed by either genomic axl or an axl cDNA.
Using an antiphosphotyrosine antibody, a novel 140-kDa
tyrosine-phosphorylated protein was seen only in cells trans-
fected with axl and not untransformed or ras-transformed
NIH 3T3 cells (Fig. 6B). Furthermore, the level of ppl40
correlated with the level of axl RNA in these cells (Fig. 6).
To further test the tyrosine kinase activity of axl, recom-
binant axl protein was expressed in Sf9 insect cells, using the
baculovirus expression system (Fig. 7). In a Coomassie-
stained polyacrylamide gel of cellular proteins, a novel
protein of approximately 104 kDa was induced in cells
infected with a recombinant baculovirus containing axl
cDNA (1-4) which was not present in wild-type-infected or
uninfected cells (Fig. 7A). The molecular size of this recom-
binant protein corresponds roughly to the predicted size (95
kDa) of the unglycosylated axl protein minus the signal
peptide as deduced from the amino acid sequence by using
the PEPTIDESORT program (Genetics Computer Group of
the University of Wisconsin [14]). Using an antiphosphoty-
rosine monoclonal antibody in Western immunoblot analy-
sis, we detected a similar 104-kDa protein in axl-baculovirus-
infected cells but not wild-type baculovirus-infected or
uninfected cells (Fig. 7B). In addition, we detected a 120-
kDa protein which we suspect represents a partially glyco-
sylated form of the ax! protein. As further evidence that the
axl-baculovirus-induced bands represent actual tyrosine-
phosphorylated proteins, the immunoreactive bands were
abolished by the inclusion of 1 mM phenylphosphate with
the antiphosphotyrosine antibody (Fig. 7B, lane 9). These
data support the conclusion that the axl protein is a tyrosine
kinase. Since insect cells do not glycosylate proteins to the
same extent as do mammalian cells, we suspect that the
140-kDa phosphoprotein seen in axl-transformed 3T3 cells
and the 120-kDa phosphoprotein in axl-infected Sf9 cells
most likely represent fully processed and partially processed
forms of axl, respectively. In support of this idea, we are
able to detect 140- and 120-kDa proteins in the axl-trans-
formed cell line AF6295 and 120- and 104-kDa proteins in
axl-baculovirus-infected Sf9 cells, using a recently isolated
polyclonal anti-ax! antibody in immunoblot analysis of cel-
lular proteins (Fig. 7C).
Cloning and characterization of c-axl. Many oncogenes
have been shown to be activated by genomic alterations (24,
50, 59, 63, 73). We investigated whether rearrangements or
deletions of axl were present in the original patient DNAs
from which axl was isolated as compared with DNAs from
normal peripheral leukocytes and from the nude mouse
tumor lines harboring the human axl oncogene. By using
probes corresponding to the kinase, transmembrane, and
extracellular domains of the cloned ax! cDNA in Southern
blot analyses, no rearrangements of axl were detected in the
DNAs from either the original CML patients or the nude
mouse tumors as compared with DNAs from normal blood
(data not shown). Furthermore, Northern blot analysis of axl
transcripts from AF6295 and several normal and trans-
formed cell types which also express axl mRNA (A549,
A431, IMR-90, HeLa, and BG-9) revealed the identical 3.4-
and 5.0-kb transcripts, making rearrangements and major
deletions unlikely (Fig. 8A).
To determine the mechanism by which axl was activated,
we cloned cDNAs of the normal axl homolog (c-ax!). Using
RNA from the normal human fibroblast IMR-90, we cloned
a normal axl cDNA (clone 4-9) which appears identical to the
transforming clone, 1-4. However, another cDNA clone
isolated from the normal fibroblast library, 6-2, predicted an
altered version of axl which lacked amino acids 429 to 437
(GQAQPVHQL) and contained a G-to-A transition at base
1170, resulting in the substitution of a leucine for a glutamic
acid (Fig. 2). We will refer to the predicted axl transcript
from 1-4 as axl+ and that from 6-2 as axl-. Reverse PCR
analysis ofRNA with oligonucleotide primers flanking amino
acids 429 to 437 showed both species of axl message present
in the nude mouse tumor cell lines as well as other human
cell lines and a primary human fibroblast, suggesting that
axl+ and axl- are splice variants from the same gene.
However, the axl+ species was overexpressed relative to the
axl- species at an average ratio of 17:1 in the nude mouse
tumor cells lines; in comparison, normal human fibroblasts
exhibited a ratio of 2:1 (Fig. 9). To test the transforming
capacity of the axl cDNA, we expressed clone 6-2 in NIH
3T3 cells by using the pLXSN retroviral expression vector.
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axl (1) 37 FVGNPGNITGARGLTGTLRCQLOVQGEPPEVHWLRDGQILELADSTQTQVPLGEDEQDDWI .... .......... VVSQLRITSLQLS.DTGQYQCLVFLGHQ
axl (2) 141 FTZEPEDRTVAANTPFNLSCQAQGPPEPVDLLLQDAVPLATAPG ....... ....................... HGPQRSLHVPGLN .KTSSFSCEAHNAKC
trk (1) 33 AAPP . DACCPHGSSG .LRCTRDGALDS .. LHHLPGAENLTELYIENQQHL.ELRDLRGLGELRN. LTIVKSGLRFVAPD
trk (2) 133 KTVQGLSLQELVLSGNPLHCSCA....... LRWLQRWEEErLGGVP.PEQKLQCHGQGPLAHMPNASCGVPTLKV
trk (3) 197 KVQVP . NASVDVCDDVLLRCQVECRGLEQ.AGWILTELEQSATVMKSGGL ....... .................. PSLGLTLANVTSDLRNKNLTCWABDVC
trk (4) 273 RAZVSVQVNVSFPASVOLHTAVEM ...... HHWSIPFSVDGQPAPSLRWLFNGSVLNETSFIFTEFLEPAANETVRHGCLRLNQPTHV. NNNYSLLANPFC
eck 52 WDLMQ.NIMNDMPIYMYSVCNVMSGDQ... DNWLRTNWVYRGEAZRNNFE................ LNFTVRDCNSFPG...CGASSCKETFNLY
elk 42 WEZVSGYDENLNTIRTYQVCNVF.EPQ... NNWLLTTFINRRGAHRIYTE................ MRFTVRDCSSLPN.VP. ..SCKETFNLY
eph 5i WSZQQ.QILNGTPLYMYQDCPMQGRRDT .. DHWLRSNWIYRGEEASRVHVE................. LQFSVRDCKSFPG.GACPLGCKETFNLL
bek (1) 43 QISQPEVYVAAPGZSLEVRCLLKDAAV ... ISWTKDGVHLGPNNRTVL .... ........... IGEYLQIKGATPR.DSGLYACTASRTVD
bek (2) 161 KMIKRLHAVPAANT .VKFRCPAGGNPMIT . MRWLKNGKEFKQEHRIGGYKVRN ..................... QHWSLIMESVVPS .DKGNY!CVVENEEYG
bek (3) 259 OAGLPANASTVVCGDVEFVCKVYSDAQPH. IQWIKHVEKNGSKYGPDGLPYLKVLKAAGVNTTDK .......... EIEVLYIRNVTFE .DAEYTCIAGNSIG
kit (3) 214 VSVSKASYLLREGBEFTVTCTIKDVSSSVYSTWKRENSQTKLQEKYNSWHHGDFNYE .................. RQATLTISSARVN.DSCVFMCYANTFG
kit (4) 316 FPMINTTVFVNDCZNVDLIVEYEAFPKIEHQQWIYMIIRTFTDKWZDYPKSENESNIR .................. YVSELHLTRLKGT.EGGTYTFLVSWSDV
kit (5) 409 VNTKPEILTYDRLVNGMLQCVAAGFPEPT. IDWYFCPGTEQRCSASVLPVDVOTLNSSGPPFGK ........... LVVQSSIDSSAFK. HNGTVECK&YRDVG
PDGFR (3) 216 VSVNAV..TVVRQGZNITLMCIVIGNEVVN . FEWTYPRKESGRLV.PVTDFLLDI4PYH .. IRSILHIPSAELE.DSCTYTCNVTESVN
PDGFR (4) 319 LGZVGTLQFAELHRSRTLQVVFEAYPPPT.VLWFKDNRTLGHDSSAGEIALSTRNVSETR . YVSELTLVRVKVA. EACHYTMRFHEDA
PDGFR (5) 418 RVLELSESHPDSB. QTVRCRGRCMPQPN. IIWSACRDLKRCPRBLPPTLLGNSSEEESQLETNVTYWEEEQEFEVVS?LRLQHVD ... RPLSVRCTLRNAVC
fms (3) 205 LTLVPAELVRIRCRAAQIVCSASSVDVNF. DVFLQHIINTKLAIPQQSDFHNNRYQ .................... KVLTLNLDQVDFQ. HAGNYSCVASWVQG
fms (4) 304 SSEQNLIQEVTVCEGLNLKVMVEAYPGLQGFNWTYLGPFSDHQPPKLANATTKDTYR ................. HTFTLSLPRLKIS .EACRYSFLaRNPGG
fms(S) 401 PPZVSVIWTFINGS . GTLLCQASCYPQPN .VTWLQCSGHTDRCDRAQVLQVWDDPYPEVLSQEPFHK ........ VTVQSLLTVETLE. HNQTYECR&HNSVG
B /---------------------------Fibronectin Type III Domain------------------------------------------------------------
[----P--L--T--T-TS ..V-W-PP---.... -TGYR----P- ---P----S-..................... T--GL-PG-EY-V-VYLV----ES-P ------T]
axl 218 TATITVLPQQPRNLHLVSRQPTELEVAWTP .GLSGI .YPLTHCT.LQAVLSDDGMGIQAG... EPDPPEEPLTSQASVPPHQLRLGSLHPHTPYHIRV.ACT ..SSQGPSSWTHWL...
trk 209 CGVPTLKVQVPNA ..SVDVGDDVL.LRCQVE.. GRGLEQAGWILTELEQ ..... SATVMKSGG..... LPSLGLTLA..... NVTSDLNRK. NLTCW ..AENDVGRAEVSVQV.
eck 322 SMPCTRPPSAPHYLTAVGM.GAKVELRWTPPQDSGGREDIVYSVT.CEQCWP ... ESGECGPCEASVRYSEPPHGLTRTS ......VTVSDLEPHMNYTFTVEARNGVSGLVTSRSFRTASVS
elk 316 EVACTSVPSGPRNVISIVN.ETSIILEWHPPRETGGRDDVTYNII.CKKCRA ... DRRSCSRCDDNVEFVPRQLGLTECR ...... VSISSLWAHTPYTFDIQAINGVSSKSPFPPQHV. SVN
eph 326 QVACTGPPSAPRNL. SFSASGTQLSLRWEPPADTGGRQDVRYSVR.CSQCQGTAQDGGPCQPCGVGVHFSPGARALTTPA ...... VHVNGLEPYANYTFNVEAQNGVSGLGSSGHAST . SVS
sev 1893 RLHVRSFAELPE.LQLLELGPYSLSLTWAGTPDPLGS ..... LQLECRSSAEQLRRNVAGNHTK...................... MVVEPLQPRTRYQCRLLLGYAATPGAPLYHGTAE...
ros 1652 TVEMFNTPEXPYSL ..VPE.NTSLQFNWKAP.. LNVN. LIRFWVELQKWKYNEFYHVKTSCSQGPAYV.............. CNITNLOPYTSYNVRVVVVYKTGENSTSLPE.
met 732 ETSIFSYREDPIVYEIHP .. TKSISTWWKEP. .NIV.... SFL.FCFASGGSTITGVGKNLNSVSV................... PRMVINVHEAGRNFTV.ACQHRSNSEII.
IRR 598 LRTLPAAPTVPQDVISTSNSSSHLLVRWKPPTQRNGN.. .LTYYLVLWQRL.AE.. DGDLYLNDYCHRGLRLPTSNNDPRF (98aa) AVLSGLRHFTEYRIDIHACNHAAHTVGCSAATFVFAR
IR 615 VQTDATNPSVPLDPISVSNSSSQIILKWKPPSDPNGN.. .ITHYLVFWER.QAE.. DSELFELDYCLKGLKLPSRTWSPP (117aa) LVISGLRHFTGYRIELQACNQDTPEERCSVAAYVSAR
IGFR 604 IRTNASVPSIPLDVLSASNSSSQLIVKWNPPSLPNGN. . LSYYIVRWQR. QPQ. .DGYLYRHNYCSKD . KIPIRKYADG (11Oaa) TVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFAR
consensus ----T--PS-P--L-SVS-----L-L-W-PP---NG-.. --Y-L--C---Q----D---------------P---LT---.. -V-S-L-P-T-Y---V-ACN--S----S---------
-----------------------------Fibronectin Type III Domain-------------------------------------------------------
[ ----P--L--T--T-TS.V-W-PP---.... -TGYR----P- --- P----S ..... ....... T--GL-PG-EY-V-VYAV--. ... --ES-P------T]
axl 325 .... PVETPEGVPL ..GPPENISATRNGSQAFVHWQEPRAPLQGTLLGYRLAYQGQDTPEVLMDIGLRQEVT ............ LELQGDGSVSNLTVCVA&YTA.AGDGPWSLPVPLEAWRP
trk 281 .... NVSFPASVQLHTAV. EMH.......... HWSIPFSVDGQPAPSLRWLFNGSVLNETSFIFTEFLEPAANETVRHGCLRLNQPTHVNNG.NYTLL ..AANP . FCQASASIMAAFMD . NP
eck 434 I.. NQTEPPKVRL..... EGRS.TTSLS ... VSWSIP.PPQQSRVWKYIVTYRKKGDSNSY ..NVRRTEGFS......... VTLDDLAPDTTYLVQVQALTQ.EGQGAGSKVHEFQTLSP
elk 427 ITT .NQAAPSTVPIMHQV.... SATRMRS. ITLSWPQPEQP .NGIILDYBIRYYEKEHNEFNS. SMARSQTNT.ARIDGLRPGMVYVVQVRARTV.AGYGKFSGKMCFQTLTD
eph 440 ISMGHAESLSGLSLRLVKKEPR ....... QLELTWAGSRPRSPGANLTYELHVLNQDEERYQMVLEPR.VLLTELQPDTTYIVRVRMLTP . LCPGPFSPDHEFRTSPP
sev 1985 ... VYETLGDAPSQPGKPQLEHIAEEVFR. VTWTAARG. NGAPIALYNLEALQARSDIRR. RRRRRRNSGGSLE (25aa) CIVKSLHSSRLLLFRVRARSLEHGWGPYSEESERVAEPF
ros 1745 .... SFKTKAGVPNKPGIPKLLEGSKNSIQ.... EKAED. .NGCRITYYILEIRKSTSNNLQNQNLRWKMTFNGSCSSV .CTWKSKNLKGIFQFRVVAANN.LGFGEYSGISENIILVG
met 808 .... CCTTPSLQQLNLQLPLKTKAFFML .............. DGILSKYFDLIYVHNPVFKPFEKPVMISMGNENVLE (38aa) NDLLKLNSELNIEWK. QLISS. TVLKVIVQPDQNFT..
IRR 809 TM.PHEADGIP......... GKVAWEASSKNSV .. LLRWLEPPDP .NGLILK!EIKYRRLGEEATVL. CVSRLRYAKFGG........ VHLALLPP .NYSARVRATSL.AGNGSWTDSVAFYILGP
IR 844 TM. .PEAKADDIV... GPVTHEIFENNVV.. HLMWQEPKEP .NGLIVLYEVSYRRYGDEELHL. CVSRKHFALERG........ CRLRGLSPG.NYSVRIRATSL.AGNGSWTEPTYFYVTDY
IGFR 825 TM. .PAEGADDIP... GPVTWEPRPENSI. .FLKWPEPENP.NGLILMYIIKYGSQVEDQRE.. CVSRQEYRKYGG........ AKLNRLNPG.NYTARIOLTSL. SGNCSWTDPVFFYVQAK
consensus --- ----P--VPL--G---------N--.. -L-W--P--P .NG--L-YE--Y- --------- - . ----P
I-Transmembrane Domain-\
axl 429 GQAQPVHQLVKEPSTPAFS....... WPWWYVLLGAVVAAACVLILALFLVHRRKKETRYGEVFEPTVERGELVVRYRVRK.... SYSRRTTE....... LTLNSLGISEELKEKLRD...
trk 383 FEFNPEDPIPDTNSTSGDPVEKKDETPFGVSVAVGLAVFACLFLSTLLLVLN]CCGRRNKFGINR.PAVLAPEDGLAMSLHFMTLGGSSLSPTEGKGSGLQGHIIE1PQYFSDACV
eck 530 ......... EGSGN.......EGS LAVIGGVAVGVVLLLVLAGVGFFIHRRRKNQRARQ ....... .................................. SPEDVYFSKSEQLKP.
elk 529 ......... DDYKSELREQ.. LPLIAGSAAAGVVFVVSLVAISIVCSR1RAY. .... SXEAVY. SDKLQHYSTGRGS
eph 539 ......... VSRGLTGGE....... IVAVIFGLLLGAALLLGILVFRSRRA.QRQRQQRHVTAPPMWIER..........................TSCAEALCGTSRHTRTLHRE...
sev 2118 ......... VSPEKRG...VSPE SLVLAIIAPAAIVSSCVLALVLVRKVQKRRLRAXKLQQSRPSIWSNLSTLQTQQQ .. .... LM&VRX.RAPSTTLSDADIALL.
ros 1853 ......... DDFWIPE...DDFW TSFILTIIVGIFLVVTIPLTFVWHRRLKNQKSAKEG.VTVLINEDKELAELRGLAA.. .... GVGLANACYAIHTLPTQEEIENL
met 951 . GLIAGVVSISTALLLLLGFFLWLKKKQIKDLGSELVRYDARVHTPHLDRLVS.... ARSVSPTTE (59aa) DLSALPELVQAVQHVV.
IRR 913 ......... EEEDAGGLH..VLLTATPVGLTLLIVLAALGFFYGIKRNRT......LYASVEYSASDM.
IR 948 ......... LDVPSNIAK ..SNIA IIIGPLIFVFLFSVVIGSIYLFLRRRQPDGPLGP ... LYASSUPEYLSASDVFPCSV...
IGFR 928 ......... TGYENFIH.LIIALPVAVLLIVGGLVIMLYVFHRKRNNSRLGNGV............................. LYSVWEYFSAADV.
consensus ..............................--I-----V------L--- -----R------ -............................. AS-P-FS------------
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C ------------------------------ Tyrosine Kinase Domain----------------------------------------------
axl 529 .......................VMVDRHKVALGKTLGEGEFGAVI.GQLNQD . DSILX .VAVK...?IAICTRSELEDFLSKAVCICEFDHNVMRLIGVCFQGSERESFPAPV .VILPF
trk 497 ....................... HHIIKRRDIVLKWELGEGAFGKVFLAECHNLLPEQDKML. ...X.. SESARQDFQREAELLTMLQHQHIVRFFGVCTEGR.......PLLMVFKY
eck 585 .. LKTYVDPHTYEDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGZVYKGMLKT.. SSGKlEVP .VAfC.LKAG . YTEKQRVDFIGEAIMQFSHHNIIRLEGVISKYK ....... PMMIITBY
elk 589 PGMKIYIDPFTYEDPNEAVREFAKBIDVSFVKIEEVIGAGEFC KGRLKLP...... GXREIYVATLKAG . YSEKQRRDFLSBASIMGQFDWNIIRLEGVVCKSR. PVMIITIF
eph 612 ........PWTL .. PGGWSNFPSRELDPAWLMVDTVIGEGEFCVYRGTLRLP .SQDCKT ... VAilTIKDTSPGG . QWWNLRATI3GQFSBHILHLEGVVTKRK.......PIMIITEF
sev 2202 .......................PQINWSQLKLLRFICSGAFGEVYEGQLKTE . DSEEPQR. .VAk SLRKGAS... EFAELLQAOQLKSNFYKENIVCLVGICFDTE .......SISLIMEH
ros 1938 ....................... PAFPREKLTLRLLLGSGAFGVYG. TAVDILGVGSGEILV GSTDQ.EKIEFLKV.HLUSKFNHNILKQ0GVCLLNE.......PQYIXILL
met 1089 ....................... IGPSSLIVHFNEVIGRGHFGCVYHGTLL ..DNDGK1IH. .CAVKSLNRITDIG.EVSQFLTEGIINlCDFSPIPNVLSLLGICLRSEGS .....PLVV.LPY
IRR 977 .................. YVPDEWYVPREQISIIREIEQGSFGMVYBG.LGRGLEAGEESTP .VALKVNELASPR .ECIEFLASVI4AFKCHErVPRLGSQGQ.....PTLVI?.SL
IR 1011 .................. YVPDEWYVSREKITLLREWBVSFGMVYTG . NARDI IKGEAETR .VIVKTVNESASLR .RIEFLNRASVIFTCHVVG TC-HSKGQV......PTLVVMBL
IGFR 987 ..................YVPDEWEVAREKITMSRELGGSFGMVYGY VAKGVVKDEPETR .VAVNETVNEAASMR.RIEFLNkSVNEFNCHI LLGVSQGQ... .PTLVIMFL
consensus ........ Z--R----L--- LG-G-FGEVYEG-L-----------.VLVKTI- ------ E-E-- -Z---F-PN1VRLLGVC--G -........P--VI-E-
axl 623 WKHGDLHSFLLYSRL ...... GDQPVYLPTQM ... LVKFMADIASGNEYLSTKRFIERDL&ILRNCNENM ....... SVCVADFGLSKKIYNGDYYR... QGRIAKMPVKWIAISLADRVY
trk 586 NRHGDLNRFLRSHGPDAKLLAGGEDVAPGPLGLGQLLAVASQVAAGhVYLAGLHFVHRDL&TRNCLVGQGL .......VVKIGDFGMSRDIYSTDYYR... VGGRTMIPIRIUPESILYRKF
eck 695 IENGALDKFLREKD ....... GEFSV.LQ ...... LVGKLRGIAAQK(TYANMNYVHRDLIARNILVNSNL .......VCKVSDFGLSRVLEDDPEATYTTSGG...KIPIRNTIPIAISYRKF
elk 700 IENGALDSYLKRQND .......GQFTV.IQ ...... LVGKILRGIAAGNKYLSEMNYVHRDLSURNILVNSNL ....... VCKVSDFCGLSRYLQDDTSDPTYTSSLGGKIPVRWTIPEAIAYRKF
eph 713 8NAALDAFLRERE ........ DQLVPGQ ......LVANLQGIASGMLSNHNYVHRDLURNILVNQNL ....... CCKVSDFGLTRLLDDFD . GTYETQGG ..KIPIRWTIPEAIAHRIF
sev 2289 IEAGDLLSYLRAAR.... ATSTQEPQPTAGLSLSELLAMCIDVANGCSYLEDMH VHRDTACPICLVTESTGSTDRRRTVKIGDFGLARDIYKSDYYR... GEGLLPVRM1iSPISLVDGLF
ros 2029 NUGGDLLTYLRKAR ... MATFYGPLLTLVD ..... LVDLCVDISKGCVYLERMHFIRDIASRCLVSVKDYTSPR. IVKIGDFGILARDIYKNDYR ...XRGEGLLPVRlNtPESLMDGIF
met 1178 MKHGDLRNFIRNET .......HNPTVKD...... LIGFGLQVAKAKYLASKKFV -DLMARSNOLDEKF ....... VADFLARDMYDKETYSVHNKTG . AXLPVKIUGKSLQTQKF
IRR 1062 MTRGDLKSHLRSLRPEAENNPGLPQPALGE ..... MIQKAGEIADGIAYTAANKrVRDLURNO4VSQDF ....... TVKIGDFGMTRDVYETDYYR ... XGGKGLLPVRWPFSLKDGIF
IR 1106 MAHGDLKSYLRSLLRPEAENNPGRPPPTLQE ..... MIQKAAEIADGMAYLNAKXFVHDLUENNIVAHDF ....... TVKIGDFGMTRDMTDYYR....KGGKGLLPVRUWPESLKDGVF
IGFR 1082 MTRGDLKSYLRSLRPEMENNPVLAPPSLSK .....MIQKAGEIADG8AYLNANKFVHRDLIAARNIVAEDF.......TVKIGDFGMTRDIYETDYYR .. KGGKGLLPVRUISPESLKDGVF
consensus ME-GDL-SFLR--R- ----G---V-L--....... LV-M ---IA-GI-YL----FVRDLAARNCLV----......... TVKIGDFGL-RDIY--DYYR ....K;G-GXaPVRViNAPESL-DR-F
.-- -*1 .\ *2
axl 727 TSKSDVISFCVTMEIATRGQTPYPGVENSIYDYLRQGNRKQPADCLDGLYALKSRCWELNPQDRPSFTILREDIENTLKALPPAQEPDEILYVNMDBGGGYPEPPGAAGGADPPTQPDPK




sev 2405 TTQSDVWAFGVLCILTLGQQPYAARNNFZVLAHVKEGGRLQQPPMCTEKLYSLLLLCRTDPWERPPSFRRCYNTLHAISTDLRRTQM.. ASATADTVVSCSRPEFKVRFDGQ .....PLEE
ros 2139 TTQSDVWSFGILI1IILTLGHQPYPAHSNLDVLNYVQTGRLEPPRNCPDDLWNLMTQCWAQEPDQRPTFHRIQNQLQLFRN .FFL ..... NSIYQCRDEANNSGVINESFEGEDGDVICLNS
met 1279 TTKSDVlSFGVLIZLMTRGAPPYPDVNTFDITVYLLQGRRLLQPEYCPDPLYEVNLKCWHPKAEMRPSFSILVSRISAIFSTFIGEHYVHVNATYVNVKCVAPYPSLLSSEDNADDEVDTRP
IRR 1170 TTHSDVSF IVTLAEQPYQGLSEQVIVMGGVLEELEGCLQLQESKSRC1 PNPRLIPSFTHILDSIQEELRPSFR ..... LLSFYYSPECRGARGS . LPTTDAEPDSSPTPR
IR 1214 TTSSDMWSFGVVLITSSLAZQPYQGLSNEQVLKFVMDGGYLDQPDNCERVTDLMRMCQFNPKMRPTFLIIVNLLLLKDDLHPSFP ..... EVSFFHSEENKAPESEELEMEFEDMENVPLDR
IGFR 1190 TTYSDVWSFGVLWEIATLAEQPYQGLSNEQV.RFVMEGGLLDKPDNCP.D.MFEUuM.IC.YNPKMRPSFLEIISSIKEEMEPGFR .....EVSFYYSEENKLPEPEELDLEPENMESVPLDP
consensus TT-SDVWSFGVVLEI-TLGEQPY--LSN-EVIX-V--GGRL--P--CP--LY-IM--CNQ--P--RPSF-EI---L----------------- S-Z------------------ P---
FIG. 3. Multiple amino acid sequence alignment of the axl protein with other receptor tyrosine kinases. Sequences were aligned by eye
according to structural similarities. Amino acid positions numbered from the initiation methionine are shown at the beginning of each
sequence. Gaps introduced for optimal alignment are designated by dots. (A) Comparison of IgL domains. Numbers in parentheses indicate
which repeat was used in the alignment. Amino acids present in six or more sequences at a given position are in bold print. Asterisks indicate
highly conserved amino acids. (B) Comparison of FNIII repeats. Shown above the sequence alignment is a consensus for FNIII domains
representing residues present in at least 7 of the 15 FNIII repeats contained in bovine fibronectin (71). Below the alignment is a consensus
sequence generated from the aligned receptor tyrosine kinases; residues present in five or more of the aligned sequences are included in the
consensus and are in bold print. The underlined sequence at amino acids 429 to 437 represents a differentially spliced exon of axl (see text).
(C) Comparison of the tyrosine kinase region. The consensus sequence listed at the bottom of each group was derived from the aligned
sequences. Parameters for bolding and the derivation for the consensus sequence are as described for panel B. *1 and *2 designate putative
autophosphorylation sites which potentially bind Ptdlns 3-kinase. Sequences are for human proteins except for elk (rat) and sevenless
(Drosophila melanogaster). Sequence sources are as follows: trk (49); eck (46); elk (44); eph (32); bek (17); kit (80); PDGFR, (25); fms (11);
sev (3); ros (6); met (59a); IRR (insulin-related receptor) (69); IR (insulin receptor) (19); and IGFR (insulinlike growth factor 1 receptor) (75).
Using the same assay as with 1-4, expression of 6-2 also blast and breast epithelium. The near-ubiquitous expression
resulted in the emergence of foci after a single passage of of axl suggests an important normal cellular function for this
G418-resistant colonies (Fig. 5). These data suggest that the receptor kinase.
activation of axl's transforming capacity is due to overex- Chromosomal localization of axl. Various cDNA fragments
pression and not to structural changes. of axl were hybridized to a Southern blot of DNAs from
Expression of axl. Using both Northern blot and differen- human-hamster somatic cell hybrids (BIOS, New Haven,
tial PCR analyses on cDNA (1, 57), variable expression of Conn.) to determine the chromosomal position of axl. All
axl was seen in most human cell lines tested, including cell results indicated that axl is located on human chromosome
lines of epithelial, mesenchymal, and hematopoietic origins 19. To determine the location of the axl gene by an indepen-
(Table 2; Fig. 8). However, AF6295 overexpresses axl dent method, we used fluorescence in situ chromosomal
relative to the other cell lines. In addition, axl was expressed hybridization of a biotin-labelled axl cosmid clone, 1-1, to
in normal, nontransformed cells, including primary fibro- normal human metaphase chromosomes. Of 25 cells exam-
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eph
Subclass
axi Similar results were obtained in a second hybridization












FIG. 4. Schematic representation of the various subclasses of
the insulin receptor family. This classification is an extension of
previously described classifications of receptor kinases (27, 76). The
dashed lines in the eph family IgL repeat indicate that this repeat
bears weak homology to IgL repeats (see Discussion).
ined, specific labelling was observed on one (4 cells), two (4
cells), three (11 cells), or all four (6 cells) chromatids of
chromosome 19 homologs; the signal was localized to the







axl encodes a receptor tyrosine kinase with high amino
acid similarity to the human trk, eph, eck, and ros proteins,
insulin and insulin-related receptor, and insulinlike growth
factor 1 receptor (Fig. 3 and 4). Novel sequence differences
in the kinase domain [i.e., KWIAIE compared with the
consensus (K/T)W(T/M)APE] set the axl protein apart from
known kinases. Supporting the conclusion that axl encodes a
tyrosine kinase, we found a novel 140-kDa tyrosine-phos-
phorylated protein in axl-transformed NIH 3T3 cells. In-
creased expression of axl RNA in these cells correlated with
increased levels of ppl40 and the tumorigenic potential of
the transformed cells in nude mice. These results are con-
sistent with the notion that ppl40 represents a phosphory-
lated axl protein. Expression of axl in baculovirus resulted in
the production of two novel tyrosine-phosphorylated pro-
teins of 104 and 120 kDa which most likely represent
unglycosylated and partially glycosylated forms of axl. The
difference in molecular size can be explained by the fact that
insect glycoproteins are processed differently from mamma-
lian glycoproteins. Both insect and mammalian cells add a
characteristic high-mannose oligosaccharide as the first step
in N-linked glycosylation (34, 36). These glycoprotein inter-
mediates are then processed to a trimannosyl core. Although
mammalian cells further process this glycosylated interme-
diate by the addition of a variety of terminal sugar residues,







FIG. 5. Analysis of axl-transformed cells. NIH 3T3 cells were transfected with expression vectors containing axl in the sense or antisense
orientation or vector alone and then selected with G418 (600 1Lg/ml; total compound). Emerging colonies from each transfection were pooled,
passaged once, allowed to grow to confluence, and assayed for focus formation. Foci emerged after 10 to 14 days in culture. Cells were then
stained with crystal violet (0.2% in H20). Samples are as follows: (A) cells transfected with cDNA clone 1-4 in the sense orientation; (B) cells
transfected with cDNA clone 1-4 in the antisense orientation; (C) cells transfected with pLXSN vector; (D) cells transfected with cDNA clone
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FIG. 6. Analysis of axl expression in transfected NIH 3T3 cells.
(A) Northern analysis. Fifteen micrograms of total RNA was
fractionated on a formaldehyde-agarose gel, transferred to nylon,
and probed with a PCR probe generated with primers PJA-14 and
PJA-17 (see Materials and Methods). Loading was normalized by
probing with an actin probe generated as described above with
actin-specific primers. Lanes: 1, TF14B1; 2, TF14B2; 3, TF14B3; 4,
TF14B4; 5, TF14B5; 6, TF14B6; 7, TF14B7; 8, TF14B8; 9, TF14B9;
10, TF14B1O; 11, TF14B11; 12, TF14B12; 13, TF14B, passage 7; 14,
TF14A; 15, TF14B; 16, TF15A; 17, TF15B; 18, TF16A; 19, TF16B;
20, AF6295. (B) Western analysis. Equivalent amounts of protein
were loaded on an 8% polyacrylamide gel, transferred to nylon, and
then immunoblotted with an antiphosphotyrosine antibody (53).
Lanes correspond to those on panel A. Sizes are indicated in
kilodaltons on the left.
fore, we suspect that the novel 140-kDa phosphoprotein in
axl-transformed 3T3 cells is a phosphorylated, fully glyco-
sylated form of axl. This conclusion is further supported by
immunoblot experiments with an anti-axl polyclonal anti-
body which reacts with what appear to be the same 120- and
140-kDa proteins seen in the antiphosphotyrosine Western
blots.
The kinase domain of axl contains two Ptdlns 3-kinase
consensus binding sites (Fig. 2). Ptdlns 3-kinase was orig-
inally found to complex with middle t antigen of polyomavi-
rus and pp6Ocsrc. Attention focused on Ptdlns 3-kinase when
it was found that association of this enzyme with transform-
ing tyrosine kinases correlated with their kinase activity and
their ability to transform cells. Various other receptors,
including the platelet-derived growth factor beta receptor
(PDGFiR), CSF-1R, and EGFR, have been shown to asso-
ciate with Ptdlns 3-kinase. In addition, receptor kinases
have been shown to complex with the ras GTPase-activating
protein and, in the case of EGFR and PDGFPiR, with
PtdIns-specific PLC--y (reviewed in reference 8). These
protein complexes are believed to play a central role in
receptor tyrosine kinase signalling pathways and are formed
by the binding of src homology regions (SH2) in proteins
such as GTPase-activating protein to the phosphorylated
receptor (8). Thus, the predicted axl peptide sequence sug-
gests that axl may also complex with Ptdlns 3-kinase.
Although similar to other receptor tyrosine kinases, the
axl protein represents a novel subclass of receptor kinases
based on the unique structure of the extracellular region that
juxtaposes IgL and FNIII repeats. Between amino acids 224
and 428 lie two FNIII repeats (Fig. 2). This sequence motif
was first identified as 60- to 100-amino-acid tandem repeats
reiterated 15 times in fibronectin (71). A number of extracel-
lular matrix proteins and receptors contain FNIII repeats,
including neural cell adhesion molecules, the growth hor-
mone/prolactin receptor family, the product of the Drosoph-
ila sevenless gene, and several receptorlike tyrosine phos-
phatases (4, 22, 29, 58, 61). In addition, we have found that
a number of mammalian tyrosine kinases, including mem-
bers of the insulin receptor family, also contain FNIII
repeats. On the basis of homologies in the kinase domain and
the presence of FNIII repeats, the axl protein appears most
closely related to the insulin receptor family (Fig. 3). How-
ever, two copies of IgL repeats encompassing amino acids
TABLE 1. Summary of tumorigenicity results
Cell line Transfected DNA Tumor latency (days)a RNA axl levelb ppl40 levelb
AF6295 Genomic axl 3 +++++ ++++
TF14A axl sense cDNA No tumors +
TF14B axl sense cDNA No tumors +
TF14B1 axl sense cDNA 7 ++++ +++++
TF14B2c axl sense cDNA 6 +++ +
TF14B3C axl sense cDNA 7 ++++ ++++
TF14B7C axl sense cDNA 4 +++++ ++++
TF14B10C axl sense cDNA 8 +++ +
TF14B (passage 7)d axl sense cDNA 7 ++++ +++++
TF15A axl antisense cDNA No tumors +
TF15B axl antisense cDNA No tumors +
TF16A Vector 43
TF16B Vector No tumors
NIH 3T3 No tumors
a Mice were observed for 50 days.
b +, qualitative difference in level; -, no expression.
c Subcloned foci from the TF14B transfectants.
d Cells from the parental transfectant, TF14B, which were pooled after foci emerged.
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FIG. 7. Coomassie blue-stained gel (A) and antiphosphotyrosine
Western blot analysis (B) of proteins from Sf9 cells infected with
wild-type or recombinant axl-baculovirus. Total cell lysates were
solubilized in sample buffer and then fractionated on a 9% polyacryl-
amide gel. (A) Lanes: 1, uninfected Sf9 cells; 2 to 4, cells infected
with wild-type baculovirus for 1, 2, and 3 days, respectively; 5 to 7,
cells infected with recombinant axl-virus for 1, 2, and 3 days,
respectively. The arrow indicates the position of the recombinant
axl protein. (B) Lanes: 1 to 7, same as in panel A; 8 and 9, identical
to lanes 1 and 6 except that 1 mM phenylphosphate was added to
block the antiphosphotyrosine antibody. (C) Western blot analysis
of total cell lysates separated on a 7.5% polyacrylamide gel, using an
antiphosphotyrosine monoclonal antibody in lanes 1 to 4 and anti-
axl polyclonal antiserum in lanes 5 to 7, 9, and 10. Lanes: 1 and 5,
untransformed NIH 3T3 cells; 2 and 6, ras-transformed 3T3 cells; 3
and 7, axl-transformed 3T3 cells (AF6295); 4, same as lane 3 except
blocked with 1 mM phenylphosphate; 8, same as lane 7 except that
rabbit preimmune serum was used as the primary antibody; 9, Sf9
cells infected for 2 days with recombinant axl-baculovirus; 10, Sf9
cells infected for 2 days with wild-type baculovirus; 11, same as lane
9 except that preimmune serum was used as the primary antibody.
Asterisks indicate partially processed ppl20 axl protein. Arrows
indicate ppl20 and ppl04 axl proteins in the axl-baculovirus-infected
cells. Sizes are indicated in kilodaltons on the left.
A 1 2 3 4 55
28s-
B
M 1 2 3 4 5 6 7 8 9 10 11 12
- \(, IN
FIG. 8. Analysis of axl expression. (A) Northern analysis. The
assay was performed as for Fig. 1 on 2 ,ug (lanes 2 to 6) or 0.5 ,ug
(lane 1) of poly(A)+ RNA except that the filter was probed with a
32P-labelled region of the kinase domain of axl generated by PCR
(35). Exposure time for lane 1 was 1 day; lanes 2 to 6 were exposed
for 7 days. The position of the 28S RNA is indicated. Lanes: 1,
AF6295; 2, A549; 3, A431; 4, IMR-90; 5, HeLa; 6, BG-9. (B) PCR
analysis of RNA isolated from various cell lines. Differential PCR
(57) was performed, using a-actin as a reference gene for semiquan-
titative analysis of axi expression. The ethidium bromide-stained
polyacrylamide gel indicates the presence of a 303-bp axl fragment
corresponding to the kinase domain and a 201-bp a-actin band as
reference. Lanes: M, HaeIII-digested marker; 1, AF6295; 2, A549;
3, A431; 4, IMR-90; 5, HeLa; 6, BG-9; 7, K562; 8, LAM; 9, CML
chronic-phase peripheral blood; 10, myelodysplastic syndrome pe-
ripheral blood; 11, normal peripheral blood 1; 12, no RNA.
37 through 212 are present amino terminal with respect to the
FNIII repeats (Fig. 2). Homologous IgL domains have also
been found in many extracellular matrix proteins and recep-
tors involved in protein-protein interactions, such as neural
cell adhesion molecules, PDGFI3R, and the leukocyte com-
mon antigen-related protein (22, 29). The combination of IgL
and FNIII repeats is seen in the neural immunoglobulin
superfamily of cell adhesion proteins and the protein ty-
rosine phosphatases. The axl protein, however, is the first
receptor tyrosine kinase identified which incorporates both
types of repeats. Though the functions of IgL and FNIII
domains are unclear, their presence in numerous cell adhe-
sion molecules and receptors suggests a potential function
for these domains in cell-cell interaction.
Receptor tyrosine kinases have been classified into fami-
lies based on sequence similarity and structural characteris-
tics (27, 76). The EGFR family contains two cysteine-rich
repeats in the extracellular domain of a monomeric receptor.
The insulin receptor family has a disulfide-linked, a2P2
heteromeric structure and contains both a cysteine-rich
domain and FNIII repeats in the extracellular region. The
PDGFRlfibroblast growth factor receptor family has an
extracellular domain that is characterized by the presence of
IgL repeats and a kinase domain that is interrupted by
various numbers of amino acids termed the kinase insert. A
number of kinases, including the trk, eph, and recently
isolated eph-related eck and elk kinases, have not been
incorporated in this classification scheme (44, 46). A detailed
amino acid sequence comparison of these receptor kinases
MOL. CELL. BIOL.
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FIG. 9. RNA-PCR expression analysis of axl isoforms. (A) Sam-
ples were analyzed for expression of the axl+ or axl- species, using
primers PJA-8 and JB-2 (see Materials and Methods), which flank
the 27-bp insertion shown in Fig. 2. Lanes: 1, AF6295; 2, AF3642; 3,
IMR-90; 4, A431; 5, K562 treated with 5 nM 12-O-tetradecanoyl-
phorbol-13-acetate; 6, negative control. (B) Different molar ratios of
cDNA clones 1-4 (axl+) and 6-2 (axl-) were mixed together and PCR
amplified (see Materials and Methods) with primers PJA-8 and JB-2
to assess the relative intensities of the different species at various
concentrations. A fraction of the product (1.5 pul) was electro-
phoresed on a 12% polyacrylamide gel and stained with ethidium
bromide. Densitometry was performed to generate a standard curve
used for comparison with samples in panel A.
with other known kinases reveals interesting structural sim-
ilarities. As with the insulin receptor family, the eph, eck,
and elk kinases contain a cysteine-rich region juxtaposed to
FNIII repeats (Fig. 4). However, in contrast to the insulin
receptor family, the eph, eck, and elk kinases are character-
ized by a vestigial IgL repeat near their amino termini and do
not contain proteolytic processing sites for the formation of
a and P subunits (Fig. 3 and 4). Thus the eph family of
kinases represents a related but distinct subclass within the
insulin receptor family. By amino acid homology, the axl
protein is most similar to the insulin receptor family. How-
ever, the extracellular domain of the axl protein lacks a
cysteine-rich region and possesses the unique juxtaposition
of two IgL and two FNIII repeats, indicating that this
protein is a separate subclass within the insulin receptor
kinase family. Although not previously described, we have
observed that the extracellular domain of the trk protein also
contains IgL and FNIII repeats, making it similar in struc-
ture to the axl protein. Interestingly, the FNIII repeats in the
trk protein closely resemble IgL repeats (Fig. 3). Bazan has
observed that IgL and FNIII domains are similar in overall
structure, suggesting that these domains evolved from a
common ancestral gene (5). It is possible, therefore, that the
trk protein represents an ancestral kinase with domains
intermediate between IgL and FNIII repeats. In view of
these sequence associations, we propose that the eph, eck,
and elk proteins represent one subclass and the axl and trk
proteins represent another subclass of receptor tyrosine
kinases that are evolutionarily related to the insulin receptor
family (Fig. 4).
In contrast to other oncogenic receptor kinase genes such
TABLE 2. Summary of axl expression
Expressiona
Sample Cell line Northern PCR
analysis analysis







Acute myelogenous SKL1 - + +
leukemia




Primary hematopoietic tissues NPB ld ND -
NPB 2 - +
CML/CPF - +
MDS 1f - -
MDS 2 - +






600 PEI - + +
Normal breast epithelia 337 - + +
Miscellaneous
Cervical cancer HeLa +++ +++
Lung cancer A549 +++ +++
Epidermoid cancer A431 +++ +++




Mouse fibroblast cell line NIH 3T3 + +++9
a Semiquantitated as follows: + + + +, very high; + + +, high; + +, moder-
ate; +, weak; -, undetectable. ND, not determined.
b Derived from secondary nude mouse tumors arising from transfection of
DNA from a patient with blast crisis CML (AF6295) or a patient with
chronic-phase CML (AF3642).
c The fragment detected was approximately 600 bp. The sequence of this
fragment was distinct from that of the axl protein and may represent a related
kinase.
d RNA was extracted from normal peripheral blood leukocytes.
RNA was extracted from peripheral leukocytes from a patient with
chronic-phase CML.
fRNA was extracted from peripheral leukocytes from a patient with
myelodysplasia.
g Analysis was done with use of only axl primers specific for the kinase
domain.
as ret, trk, and fms (CSF-1R), the normal c-axl gene was
activated by overexpression rather than by genomic alter-
ations such as mutation or rearrangement. Overexpression
of normal receptors (e.g., erbB2) can also result in neoplastic
transformation in an apparently ligand-independent fashion
(16). Transfection of axl cDNA into 3T3 cells indicates that
selection for cells overexpressing axl is required for mani-
festation of the transformed phenotype; low-level expression
is insufficient for neoplastic transformation. Furthermore,
we have identified two distinct variants of axl receptor
present in both the nude mouse tumor cell lines and normal
cells but expressed at different ratios in these samples.
Presumably these two forms are derived by differential
splicing of an alternative exon. Similar structural variation is
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FIG. 10. In situ hybridization of a biotin-labelled axl probe to human metaphase cells from phytohemagglutinin-stimulated peripheral
blood lymphocytes. (A) Counterstained with 2,4-diamidino-2-phenylindole dihydrochloride; (B) detection of the probe with fluorescein
isothiocyanate-conjugated avidin (45). The chromosome 19 homologs are identified with arrows; specific labelling was observed at 19q13.2.
(C) Partial karyotype of a chromosome 19 homolog illustrating specific labelling at 19q13.2.
seen in the generation of the insulin receptor in which a
36-nucleotide exon (exon 11) coding for a portion of the
extracellular domain is spliced into the transcript in some
tissues and not in others (67). Though the function of this
differential splicing event in both the insulin receptor and the
axl protein remains unclear, our data indicate that both
forms of the axl protein are biologically indistinguishable in
terms of their transforming capacity in NIH 3T3 cells. This
also suggests that the substitution of leucine for glutamic
acid at amino acid 338 represents a sequence polymorphism
as opposed to an activating mutation. This view is further
supported by the finding that another cDNA clone (clone 4-9)
from the normal human fibroblast cDNA library has the same
sequence as clone 1-4 with regard to amino acid 338 and the
presence of the 27-base insert. These observations are con-
sistent with the conclusion that axl transformation is due to
overexpression of a normal receptor tyrosine kinase. Similar
to axl, the eph gene has been shown to have weak transform-
ing properties when overexpressed in 3T3 cells (51).
Several lines of evidence underscore the potential role of
axl in normal cellular function. First, the transforming activ-
ity of axl suggests a role for the proto-oncogene in prolifer-
ation. Second, axl expression can be detected in the majority
of cell types examined, implying a significant role for axl in
normal cellular activity. This notion is further supported by
the near-ubiquitous expression of axl message in various
mouse organs (58a). Third, axl expression is altered in
hematopoietic differentiation. axl RNA levels are augmented
>10-fold in the CML cell line K562 upon addition of the
phorbol ester 12-O-tetradecanoylphorbol-13-acetate), which
induces megakaryoblastic differentiation in these cells (57a,
74). Using a PCR-based cloning strategy, Partanen et al. (60)
have detected novel tyrosine kinases expressed in differen-
tiated K562 cells. One of these partial cDNA clones, desig-
nated JTK 11, has the same sequence as the axl protein at
amino acids 669 through 736 in the kinase domain (60).
The specific role of axl in the pathogenesis of CML
remains unclear. However, our data suggest that axl is a
CML-associated oncogene. First, identical forms of axl
emerged as the transforming gene in two of eight non-mutant
ras-bearing CML cases analyzed in a transfection-tumorige-
nicity assay (47). We have applied this assay on >40 DNAs
from numerous malignancies (breast carcinomas, squamous
cell carcinomas of the skin, renal cell carcinomas, and other
types of leukemias) and have not uncovered axl in any
transformant (46a). Thus, an oncogenic axi gene has been
found only in CML samples. Since axl-induced transforma-
tion of 3T3 cells results from overexpression of the trans-
fected proto-oncogene, these two CML samples may contain
mutations in the axi promoter or as yet uncloned 5' untrans-
lated sequences which may result in overexpression of the
axl kinase. Activation of the Ick proto-oncogene occurs
through a similar mechanism in which mutations in the 5'
untranslated region increase the translational efficiency of the
gene, resulting in overexpression of the oncoprotein (48).
Characterization of the axl promoter region will address this
possibility. In addition, using chromosomal in situ hybridiza-
tion (45), we have localized axl to chromosome 19, band q13.2
(Fig. 10), where another oncogene, bcI3, is also found
(19q13.1-13.2) (42, 54). Interestingly, chromosome 19 abnor-
malities (especially trisomy 19) are frequently associated with
the conversion of chronic-phase CML to blast phase occur-
ring in approximately 18% of blast crisis samples (64). Future
studies will help define axl's role in human malignancies.
ACKNOWLEDGMENTS
We thank Eleni Levedakou for helpful discussions, Bernard
Weissman for critical reading of the manuscript, Paul Bates (UCSF)
for the cosmid vectors, Helene Smith for 337 RNA and the 600 PEI
cell line, Jack W. Singer for EM2, Armand Keating for EM3, Jun
Hayashi for KOPM-28, Ronald Levy for LAM and DHL-4, Daynise
MOL. CELL. BIOL.
axl, A NOVEL, TRANSFORMING RECEPTOR TYROSINE KINASE 5029
Skeen and Yogesh Patel for technical assistance, and J. Michael
Bishop for his support of the initial phases of this work.
This work was supported by the following grants: ACS PDT-395
(E.T.L.), NCI RO1-CA49240 (E.T.L.), Deutsche Forschungsge-
meinschaft Ne310/4-1 (A.N.), and Deutsche Krebsgesellschaft Ber-
lin (A.N.). J.P.O. is a Howard Hughes Medical Institute predoctoral
fellow; R.A.F. is supported by a Clinical Oncology Career Devel-
opment Award from the American Cancer Society; E.T.L. is a
special fellow of the Leukemia Society of America; M.M.L. is a
scholar of the Leukemia Society of America.
ADDENDUM
Using the same transfection assay as described in this
report, Janssen et al. (35a) have identified the identical gene,
which they call UFO, in DNA from a patient with chronic
myeloproliferative disease.
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